2040. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J, Kim S, Kim MY, Go H, Jeon YK, Chung DH
Oncotarget. 2017 Feb 21;8(8):13762-13769. doi: 10.18632/oncotarget.14632.Link
2039. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH.
Lung Cancer. 2017 Apr;106:131-137. doi: 10.1016/j.lungcan.2017.02.008. Epub 2017 Feb 16.Link
2038. Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.
Cho N, Im SA, Cheon GJ, Park IA, Lee KH, Kim TY, Kim YS, Kwon BR, Lee JM, Suh HY, Suh KJ
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):328-339. doi: 10.1007/s00259-017-3849-3. Epub 2017 Nov 4.Link